Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double-blind, placebo-controlled, dose-ranging partial-block crossover study to investigate the effect of intravenous oliceridine on CNS functioning and nociceptive thresholds in healthy subjects, compared to morphine.

Next Previous
Trial Profile

A randomised, double-blind, placebo-controlled, dose-ranging partial-block crossover study to investigate the effect of intravenous oliceridine on CNS functioning and nociceptive thresholds in healthy subjects, compared to morphine.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oliceridine (Primary) ; Morphine
  • Indications Acute pain; Postoperative pain; Respiratory tract disorders
  • Focus Therapeutic Use
  • Sponsors Trevena

Most Recent Events

  • 08 Dec 2022 According to a Trevena media release, data from this study were presented at the American College of Neuropsychopharmacology (ACNP) Annual Meeting.
  • 28 Jul 2022 Primary endpoint (Neurocognitive function is measured using the saccadic eye movements peak velocity (/s) at pre-dose, 30min, 1, 2 , 3, 4, 5, and 6 h.) has been met, according to a Trevena media release.
  • 28 Jul 2022 Positive topline results published in the Trevena Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top